In early to locally advanced stages of breast cancer, neoadjuvant (preoperative) therapy with HER2-targeted medicines has shown to increase the chance of achieving pathological complete response (pCR) as well as improve survival8–13. The gene discussed is ERBB2; the disease is breast carcinoma.